Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the ...

Biogen Inc. (NASDAQ:BIIB) was among Jim Cramer’s stock calls on Mad Money recently. Toward the end of the lightning round, a ...

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) has been upgraded to ‘Buy’ from ‘Neutral’ by UBS analysts, who also raised their price ...

April 20 (Reuters) - Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater ...

UBS analyst Michael Yee upgraded Biogen to Buy from Neutral and raised the price target to $225 from $185 in a note on Wednesday, citing a concentrated window of pipeline catalysts over the next 12 to ...

Biogen (BIIB) has reached a deal worth up to $850M with TJ Bio to acquire exclusive rights in Greater China for felzartamab, an antibody therapy designed to target various immune-mediated disorders, ...

Biogen has agreed to acquire ​Apellis ​Pharmaceuticals ​for about $5.6 billion in cash, expanding its portfolio ⁠of ‌rare-disease medicines.

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial FDA approval for failed Alzheimer’s treatment Aduhelm. | Biogen has agreed ...

Biogen has agreed to pay up to $850 million to acquire TJ Bio's exclusive rights to felzartamab in the Greater China region, giving it worldwide rights to the investigational drug that is currently in ...

Biogen (BIIB) stock gains as Piper Sandler upgrades the company, citing positives in the company’s recent deal to acquire eye ...

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights ...

Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis Pharmaceuticals ...